Antisense compounds, compositions and methods are provided for modulating the expression of RAIDD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RAIDD. Methods of using these compounds for modulation of RAIDD expression and for treatment of diseases associated with expression of RAIDD are provided.
Claims What is claimed is: 1. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 40, 41, 43, 44, 45, 46, 47, 48, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 64, 65, 66, 68, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 167, 168, 169, 170, 171, 172, 173, 176 or 177 which compound specifically hybridizes with a nucleic acid encoding RAIDD and inhibits the expression of RAIDD. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The compound of claim 4 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A method of inhibiting the expression of RAIDD in human cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of RAIDD is inhibited. 11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11 further comprising a colloidal dispersion system. 13. The composition of claim 11 wherein the compound is an antisense oligonucleotide. 